Si-Bone Inc (SIBN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Si-Bone Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Analysts & Price Target
The price target sits 35.6% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.15 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.11 | – | 49 | 26.10 | -9.20 | 1 | -1 |
| 2025: Q1 | -0.15 | – | 47 | 24.90 | -13.80 | -5 | -7 |
| 2025: Q2 | -0.14 | – | 49 | 21.70 | -12.70 | 0 | -2 |
| 2025: Q3 | -0.11 | – | 49 | 20.60 | -9.40 | 2 | -1 |
| 2025: Q4 | -0.04 | – | 56 | 15.00 | -2.90 | 2 | 0 |
| 2026: Q1 | -0.10 | – | 53 | 11.20 | -8.20 | -2 | -3 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
SI-BONE, Inc., ein Medizinprodukteunternehmen, entwickelt verfahrenstechnische Lösungen für geschwächte Knochen, gestützt auf Expertise in biomechanischem Design und anatomiespezifischen Anwendungen, in den USA und international.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 376 |
| Headquarters | Santa Clara, CA |
| Website | si-bone.com |
| IPO Date | 17. Oct 2018 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey W. Dunn | Executive Chairman | 1956 |
| Laura A. Francis MBA | CEO & Director | 1967 |
| Anshul Maheshwari | COO & CFO | 1980 |
| Michael A. Pisetsky J.D. | Chief Business & Legal Affairs Officer, Secretary and General Counsel | 1978 |
| Anthony J. Recupero | Advisor | 1960 |
| Scott A. Yerby Ph.D. | Senior VP of Engineering & CTO | 1968 |
| Saqib Iqbal | Vice President of Financial Planning & Analysis and Investor Relations | – |
| Ian Bailey | Vice President of Product & Marketing | – |
| Daniel Joseph Cher M.D. | Senior Vice President of Clinical, Regulatory Affairs & Quality | 1965 |
| W. Carlton Reckling M.D. | Chief Medical Officer & VP of Medical Affairs | 1963 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.